Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124456054> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2124456054 endingPage "727" @default.
- W2124456054 startingPage "723" @default.
- W2124456054 abstract "Background: Anthracyclines and taxanes have historically constituted the backbone of chemotherapy regimens for patients with breast cancer positive for the human epidermal growth factor receptor 2 (HER2). For a subset of patients who categorically refuse alopecia, or for those with a contraindication to those drugs, there is an urgent need to define alternative regimens. Here, we report our institutional experience with trastuzumab and vinorelbine (TV), a combination with good clinical activity and a good side effect profile for patients with HER2-positive breast cancer. Methods: In a retrospective analysis, outcomes data were extracted for patients receiving TV as their only chemotherapy in the non-metastatic setting at the Jewish General Hospital. For the most part, TV was administered weekly for 6 months, followed by trastuzumab for 6 months. Results: The analysis identified 46 patients (mean age: 64 years) who received TV between 2003 and 2012 (n = 36 adjuvant, n = 10 neoadjuvant). Of the patients in the adjuvant group, 81% had stage i disease. In the neoadjuvant group, 3 patients experienced a complete pathologic response. Only 1 patient experienced local recurrence after a short course (3 months) of adjuvant TV. Overall survival and breast cancer–specific survival were 94% and 98% respectively at a median 5 years of follow-up. Febrile neutropenia–induced sepsis resulted in the death of 1 patient with significant medical comorbidities; 2 other patients died of comorbidities unrelated to their cancer or treatment. Grades 3 or 4 adverse events included neutropenia (23%), febrile neutropenia (10%), fatigue (2%), and anemia (2%). Conclusions: For patients with non-metastatic breast cancer refusing alopecia, or for patients who are not candidates for standard chemotherapy, TV is a reasonable alternative to standard adjuvant chemotherapy." @default.
- W2124456054 created "2016-06-24" @default.
- W2124456054 creator A5034804495 @default.
- W2124456054 creator A5049481562 @default.
- W2124456054 creator A5055778877 @default.
- W2124456054 creator A5088884805 @default.
- W2124456054 date "2014-10-01" @default.
- W2124456054 modified "2023-09-29" @default.
- W2124456054 title "The Trastuzumab and Vinorelbine Combination: An Alternative to Taxane-Based Chemotherapy for Early-Stage and Locally Advanced HER2-Positive Breast Cancer" @default.
- W2124456054 cites W1836239578 @default.
- W2124456054 cites W1986405458 @default.
- W2124456054 cites W1988737162 @default.
- W2124456054 cites W2009402447 @default.
- W2124456054 cites W2035484878 @default.
- W2124456054 cites W2098775844 @default.
- W2124456054 cites W2108182027 @default.
- W2124456054 cites W2113450161 @default.
- W2124456054 cites W2127457632 @default.
- W2124456054 cites W2144124503 @default.
- W2124456054 cites W2146384083 @default.
- W2124456054 cites W2149908785 @default.
- W2124456054 cites W2159305151 @default.
- W2124456054 doi "https://doi.org/10.3747/co.21.2069" @default.
- W2124456054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4189578" @default.
- W2124456054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25301539" @default.
- W2124456054 hasPublicationYear "2014" @default.
- W2124456054 type Work @default.
- W2124456054 sameAs 2124456054 @default.
- W2124456054 citedByCount "7" @default.
- W2124456054 countsByYear W21244560542015 @default.
- W2124456054 countsByYear W21244560542016 @default.
- W2124456054 countsByYear W21244560542017 @default.
- W2124456054 countsByYear W21244560542023 @default.
- W2124456054 crossrefType "journal-article" @default.
- W2124456054 hasAuthorship W2124456054A5034804495 @default.
- W2124456054 hasAuthorship W2124456054A5049481562 @default.
- W2124456054 hasAuthorship W2124456054A5055778877 @default.
- W2124456054 hasAuthorship W2124456054A5088884805 @default.
- W2124456054 hasBestOaLocation W21244560541 @default.
- W2124456054 hasConcept C121608353 @default.
- W2124456054 hasConcept C126322002 @default.
- W2124456054 hasConcept C141071460 @default.
- W2124456054 hasConcept C143998085 @default.
- W2124456054 hasConcept C2776694085 @default.
- W2124456054 hasConcept C2777063308 @default.
- W2124456054 hasConcept C2777511904 @default.
- W2124456054 hasConcept C2778239845 @default.
- W2124456054 hasConcept C2778850193 @default.
- W2124456054 hasConcept C2779786085 @default.
- W2124456054 hasConcept C2780350996 @default.
- W2124456054 hasConcept C2781190966 @default.
- W2124456054 hasConcept C530470458 @default.
- W2124456054 hasConcept C71924100 @default.
- W2124456054 hasConceptScore W2124456054C121608353 @default.
- W2124456054 hasConceptScore W2124456054C126322002 @default.
- W2124456054 hasConceptScore W2124456054C141071460 @default.
- W2124456054 hasConceptScore W2124456054C143998085 @default.
- W2124456054 hasConceptScore W2124456054C2776694085 @default.
- W2124456054 hasConceptScore W2124456054C2777063308 @default.
- W2124456054 hasConceptScore W2124456054C2777511904 @default.
- W2124456054 hasConceptScore W2124456054C2778239845 @default.
- W2124456054 hasConceptScore W2124456054C2778850193 @default.
- W2124456054 hasConceptScore W2124456054C2779786085 @default.
- W2124456054 hasConceptScore W2124456054C2780350996 @default.
- W2124456054 hasConceptScore W2124456054C2781190966 @default.
- W2124456054 hasConceptScore W2124456054C530470458 @default.
- W2124456054 hasConceptScore W2124456054C71924100 @default.
- W2124456054 hasIssue "5" @default.
- W2124456054 hasLocation W21244560541 @default.
- W2124456054 hasLocation W21244560542 @default.
- W2124456054 hasLocation W21244560543 @default.
- W2124456054 hasLocation W21244560544 @default.
- W2124456054 hasOpenAccess W2124456054 @default.
- W2124456054 hasPrimaryLocation W21244560541 @default.
- W2124456054 hasRelatedWork W1966804628 @default.
- W2124456054 hasRelatedWork W2003291927 @default.
- W2124456054 hasRelatedWork W2003831525 @default.
- W2124456054 hasRelatedWork W2016027388 @default.
- W2124456054 hasRelatedWork W2092771806 @default.
- W2124456054 hasRelatedWork W2092900344 @default.
- W2124456054 hasRelatedWork W2142770096 @default.
- W2124456054 hasRelatedWork W2147874203 @default.
- W2124456054 hasRelatedWork W2224432166 @default.
- W2124456054 hasRelatedWork W65154174 @default.
- W2124456054 hasVolume "21" @default.
- W2124456054 isParatext "false" @default.
- W2124456054 isRetracted "false" @default.
- W2124456054 magId "2124456054" @default.
- W2124456054 workType "article" @default.